Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis

J Gastroenterol. 2011 Mar;46(3):415-6; author reply 417. doi: 10.1007/s00535-010-0356-8. Epub 2010 Dec 22.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticholesteremic Agents / pharmacology*
  • Anticholesteremic Agents / therapeutic use
  • Azetidines / pharmacology*
  • Azetidines / therapeutic use
  • Carrier Proteins / metabolism*
  • Ezetimibe
  • Fatty Liver / drug therapy
  • Fatty Liver / metabolism
  • Humans
  • Non-alcoholic Fatty Liver Disease

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Carrier Proteins
  • microsomal triglyceride transfer protein
  • Ezetimibe